209eP Real-world experience with trastuzumab deruxtecan in metastatic ERBB2-altered non-small cell lung cancer | Synapse
March 21, 2026Open Access
209eP Real-world experience with trastuzumab deruxtecan in metastatic ERBB2-altered non-small cell lung cancer
Key Points
The aim is to evaluate the effectiveness of trastuzumab deruxtecan as a second-line treatment for metastatic ERBB2-altered non-small cell lung cancer after immunotherapy.
Analyzed patient outcomes after treatment with trastuzumab deruxtecan
Included patients who had progressed after first-line immune checkpoint inhibitors
Focus on real-world effectiveness and treatment strategies
No significant differences in treatment effectiveness observed based on treatment strategies
Trastuzumab deruxtecan provides a potential option for patients after ICI progression
Abstract
second-line therapy in patients after progression of first-line ICIs therapy does not show significant differences due to the type of treatment strategies.